Zealand Pharma A/S (OCSE:ZEAL) Net Change in Cash : kr-619.9 Mil (TTM As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Zealand Pharma A/S Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Zealand Pharma A/S's Net Change in Cash for the three months ended in Dec. 2023 was kr64.9 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was kr-619.9 Mil.

Zealand Pharma A/S Net Change in Cash Historical Data

The historical data trend for Zealand Pharma A/S's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Net Change in Cash Chart

Zealand Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

220.43

-120.84

168.88

-59.87

-619.92

Zealand Pharma A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Change in Cash	Get a 7-Day Free Trial															575.48	-238.16	-503.39	56.76	64.87

Zealand Pharma A/S Net Change in Cash Calculation

Zealand Pharma A/S's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-425.668	+	-1094.033	+	907.014	+	-7.237
	=	-619.9

Zealand Pharma A/S's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 59.515 + 6.698 + 5.598 + -6.942

= 64.9

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-619.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zealand Pharma A/S Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Zealand Pharma A/S's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma A/S (OCSE:ZEAL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OCSE:ZEAL) » Definitions » Net Change in Cash

Comparable Companies

OCSE:ALK B OCSE:BAVA OCSE:GUBRA OCSE:PEG A OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122 ALNY OCSE:GMAB XKRX:068270 BMRN

Traded in Other Exchanges

ZLDPF:USA ZEALc:UK 0NZU:UK 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma A/S (OCSE:ZEAL) Headlines

From GuruFocus

Zealand Pharma announces directed issue and private placement corresponding to approx. 6.6 % of existing share capital
By PurpleRose PurpleRose • 07-11-2022

Zealand Pharma Hosts Conference Call on November 10 at 4pm CET (10am ET) to Present Third Quarter Results for 2022
By Value_Insider Value_Insider • 11-03-2022

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
By PurpleRose PurpleRose • 08-18-2022

Zealand Pharma Presents Data from Phase 1 Trial of Dapiglutide at the 82nd Annual American Diabetes Association Scientific Sessions and Announces Dapiglutide to Move into Phase 2 Trial for Obesity
By GuruFocusNews GuruFocusNews • 07-07-2022

Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities
By GuruFocusNews GuruFocusNews • 07-04-2022

Zealand Pharma completes registration of capital increase
By GuruFocusNews GuruFocusNews • 07-03-2022

Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)
By GuruFocusNews GuruFocusNews • 07-08-2022

Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities [CORRECTED]
By PurpleRose PurpleRose • 07-11-2022

Zealand Pharma Amends Financing Agreement with Oberland Capital as Part of Company's Refocused Strategy
By GuruFocusNews GuruFocusNews • 07-09-2022

Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting
By Value_Insider Value_Insider • 11-01-2022